Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports prior receipt on 19 March 2024 and 5…
Thu, 10 Oct 2024 22:40:00 GMT Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.
Wed, 09 Oct 2024 08:16:00 GMT Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
Wed, 09 Oct 2024 06:18:00 GMT After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...
Tue, 08 Oct 2024 17:09:00 GMT No. 48 / 2024Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinismU.S. Food and ...
Tue, 08 Oct 2024 15:37:00 GMT The U.S. health regulator has declined to approve Zealand Pharma's drug to prevent and treat low blood sugar in children with a genetic disorder, the Danish biotech firm said on Tuesday, marking the ...
